Wezlana: The First Stelara Biosimilar to Launch in the US

This text details the arrival of Wezlana, the first interchangeable biosimilarto the blockbuster drug Stelara, marking a shift toward more affordable treatment options for autoimmune and gastrointestinal diseases. By securing an interchangeability status, this new medication can be substituted by pharmacists without a provider's intervention, potentially increasing patient access while addressing the high costs of the original biologic. The article highlights a competitive landscape where several other biosimilars are poised to enter the market in 2025, yet it warns that market adoption may be hindered by "product hopping," a strategy where manufacturers move patients to newer patented drugs to avoid competition. Ultimately, the source examines whether these new alternatives will successfully capture market share or if they will face the same hurdles seen in previous biologic transitions.